CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
Clofarabine +8 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02135874
NCT02135874Phase 2Completed
CompareCT.gov

A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids for Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

M.D. Anderson Cancer Center·interventional·Posted May 12, 2014·Updated Mar 22, 2024

In Brief

A Phase 2 clinical trial evaluating Clofarabine, Cytarabine, and 7 other interventions for Acute Bilineal Leukemia and 7 related conditions. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This phase II trial studies how well clofarabine, idarubicin, cytarabine, vincristine sulfate, and dexamethasone work in treating patients with mixed phenotype acute leukemia that is newly diagnosed or has returned after a period of improvement (relapsed). Drugs used in chemotherapy, such as clofarabine, idarubicin, cytarabine, vincristine sulfate, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified, Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified, Recurrent Mixed Phenotype Acute Leukemia
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 12, 2014
Enrollment StartOct 27, 2014
Primary CompletionFeb 21, 2023
TodayJul 1, 2026
Enrollment to primary: 8.3 yearsPosted 12.1 years ago

Interventions

Clofarabinedrug

Given IV

Cytarabinedrug

Given IV

Dexamethasonedrug

Given IV

Idarubicindrug

Given IV

Rituximabbiological

Given IV

Sorafenibdrug

Given PO

Sorafenib Tosylatedrug

Given PO

Vincristinedrug

Given IV

Vincristine Sulfatedrug

Given IV